Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma
Clinical trial NCT03168438 · TERMINATED
Trial details
- NCT number
- NCT03168438
- Sponsor
- GlaxoSmithKline
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-08-18
- Primary completion
- 2020-07-13
- Enrollment
- 6
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.